1-(3-aminopropyl) substituted cyclic amine compounds, preparation method therefor, and pharmaceutical compositions and uses thereof

1. A compound of formula I, a pharmaceutically acceptable salt, enantiomer, diastereoisomer, racemate or mixture thereof,

wherein,

W is absent or —CH 2 CH 2 —;

X is N or CR 6 ;

R 1 is selected from a 5 to 7-membered heteroaryl unsubstituted or substituted with 1-3 substituents, wherein said heteroaryl contains 1 to 3 heteroatoms selected from oxygen, sulfur or nitrogen and each of said substituents is independently selected from a halogen, a C1-C4 straight or branched alkyl, a C1-C4 straight or branched haloalkyl, a C1-C4 straight or branched alkyloxy, a C1-C4 straight or branched chain haloalkoxy, —NR 10 R 11 , —C(═O)R 12 , a C1-C4 straight or branched alkanoyloxy, a cyano, a nitro and a hydroxy, or two adjacent R 1 substituents with the atoms to which each is attached are combined to form a fused 5-7 membered ring;

each of R 10 and R 11 is independently selected from a group consisting of H, a C1-C4 straight or branched alkyl and —C(═O)R 13 ;

R 12 is selected from a group consisting of a C1-C4 straight or branched alkyl, a C1-C4 straight or branched alkyloxy, a hydroxyl, an amino (NH 2 ) and a C1-C4 straight or branched alkylamino;

R 13 is selected from a group consisting of H and a C1-C4 straight or branched alkyl;

R 2 is selected from the following groups unsubstituted or substituted with 1-3 substituents: a C1-C6 straight or branched alkyl, a C3-C7 cycloalkyl, a 4 to 7-membered heterocyclic group, a C6-C12 aryl or a 5-7 membered heteroaryl; wherein, said substituent is selected from a group consisting of a halogen, a hydroxy, a C1-C4 straight or branched alkyl, a C1-C4 straight or branched haloalkyl, a C1-C4 straight or branched alkyloxy, a C1-C4 straight or branched alkyl carbonyl, a C1-C4 straight or branched haloalkoxy, a C1-C4 straight or branched alkylsulfonyl group, a C1-C4 straight or branched alkylsulfonylcarbamoyl, a tetrazolyl, a cyano, a nitro, an amino, a carboxy, a phenyl, a halophenyl, a phenoxy, and a halophenoxy;

each of R 3 , R 4 and R 5 is independently selected from a group consisting of H, a C1-C6 straight or branched alkyl and a C3-C7 cycloalkyl;

R 6 is selected from a group consisting of H and a C1-C6 straight or branched alkyl; alternatively, R 5 and R 6 may bind together with

 to form

R 7 is selected from a group consisting of H, C(═O)R 8 , C(═O)OR 8 , C(═O)NR 8 R 9, SO 2 R 8 and the following groups substituted by 1-3 substituents a C1-C6 straight or branched alkyl, a C3-C7 cycloalkyl, a 4 to 7-membered heterocyclic group, a benzyl, a C6-C12 aryl and a 5-7 membered heteroaryl; wherein said substituent is selected from a halogen, a hydroxy, a C1-C4 straight or branched alkyloxy, a C1-C4 straight or branched alkyl, a C1-C4 straight or branched haloalkyl, a C1-C4 straight or branched haloalkoxy, a cyano, a nitro, an amino and a carboxyl;

each of R 8 and R 9 is independently selected from a group consisting of a hydrogen and the following groups unsubstituted or substituted with 1-3 substituents: a C1-C6 straight or branched alkyl, a C3-C7 cycloalkyl, a 4-7 membered heterocyclic group, a benzyl, a C6-C12 aryl and a 5-7 membered heteroaryl; wherein said substituent is selected from a group consisting of a halogen, a hydroxy, a C1-C4 straight or branched alkoxy, a C1-C4 straight or branched alkyl, a C1-C4 straight or branched haloalkyl, a C1-C4 straight or branched haloalkoxy, a cyano, a nitro, an amino, and a carboxyl.

2. The compound according to claim 1 , a pharmaceutically acceptable salt, enantiomer, diastereoisomer, racemate or mixture thereof, wherein,

R 1 is selected from the following groups unsubstituted or substituted with 1-3 substituents:

 said substituent is defined as claim 1 ;

each of R 10 and R 11 is independently selected from a group consisting of H, a C1-C2 alkyl and —C(═O)R 13 ;

R 12 is selected from a group consisting of a C1-C2 alkyl, a C1-C2 alkoxy, a hydroxy, an amino (NH 2 ) and a C1-C2 alkylamino;

R 13 is selected from a group consisting of H and a C1-C2 straight or branched alkyl;

R 2 is selected from the following groups unsubstituted or substituted with 1-3 substituents: a C1-C4 straight or branched alkyl, a C3-C7 cycloalkyl, a 4-7 membered heterocyclic group and a phenyl, wherein, said substituent is selected from a group consisting of a halogen, a hydroxy, a C1-C4 straight or branched alkyl, a C1-C4 straight or branched haloalkyl, a C1-C4 straight or branched alkoxy, a C1-C4 straight or branched alkylcarbonyl, a C1-C4 straight or branched haloalkoxy, a C1-C4 straight or branched alkylsulfonyl, a C1-C4 straight or branched alkylsulfonylcarbamoyl, a tetrazolyl, a cyano, a nitro, an amino, a carboxyl, a phenyl, a halophenyl, a phenoxy and a halophenoxy;

each of R 3 , R 4 and R5 is independently selected from a group consisting of H, a C1-C4 straight or branched alkyl and a C3-C7 cycloalkyl;

R 6 is selected from a group consisting of H and a C1-C4 straight or branched alkyl,

or R 5 and R 6 can bind together with

 to form

R 7 is selected from a group consisting of H, C(═O)R 8 , C(═O)OR 8 , C(═O)NR 8 R 9, SO 2 R 8 and the following groups substituted with 1-3 substituents: a C1-C4 straight or branched alkyl, a C3-C7 cycloalkyl, a 4-7 membered heterocyclic group, a benzyl and a phenyl, wherein, said substituent is selected from a group consisting of a halogen, a hydroxy, a C1-C4 straight or branched alkoxy, a C1-C4 straight or branched alkyl, a C1-C4 straight or branched haloalkyl, a C1-C4 straight or branched haloalkoxy, a cyano, an nitro, an amino and a carboxyl; each of R 8 and R 9 is independently selected from a group consisting of H and the following groups unsubstituted or substituted with 1-3 substituents: a C1-C4 straight or branched alkyl, a C1-C4 straight or branched haloalkyl, a C3-C7 cycloalkyl, a 4-7 membered heterocyclic group, a benzyl, a phenyl and a 5-7 membered heteroaryl, wherein, said substituent is selected from a group consisting of a halogen, a hydroxy, a C1-C4 straight or branched alkoxy, a C1-C4 straight or branched alkyl, a C1-C4 straight or branched haloalkyl, a C1-C4 straight or branched haloalkoxy, a cyano, a nitro, an amino and a carboxyl.

3. The compound according to claim 2 , a pharmaceutically acceptable salt, enantiomer, diastereoisomer, racemate or mixture thereof, wherein said substituent on R 1 is selected from a group consisting of a halogen, a C1-C2 alkyl, a C1-C2 haloalkyl, a C1-C2 alkoxy, NR 10 R 11 , —C(═O)R 12 , a C1-C2 alkylcarbonyloxy, a C1-C2 haloalkoxy, a cyano, a nitro and a hydroxyl, or two adjacent R 1 substituents with the atoms to which each is attached are combined to form a fused 5-7 membered carbocycle, 5-7 membered heteroaryl ring or 5-7 membered heterocycle.

4. The compound according to claim 3 , a pharmaceutically acceptable salt, enantiomer, diastereoisomer, racemate or mixture thereof, wherein said substituent on R 1 is selected from a group consisting of a halogen, a methyl, a methoxy, an ethyl, an amino, a hydroxy, a formamido, an acetamido, a carbamoyl, N-methylcarbamoyl, N,N-dimethylcarbamoyl, a formyloxy, an acetoxy, a methoxycarbonyl, a trifluoromethyl, a cyano, a nitro, an acetyl and a trifluoromethoxy, or two adjacent R 1 substituents together with the atoms to which each is attached form a benzene ring, a cyclopentene ring or dioxole ring.

5. The compound according to claim 4 , a pharmaceutically acceptable salt, enantiomer, diastereoisomer, racemate or mixture thereof, wherein R 2 is selected from a C1-C4 straight or branched alkyl, a cyclopropyl, a cyclobutyl, a cyclopentyl, a cyclohexyl, a tetrahydropyran-4-yl, a 1-methylpiperidin-4-yl, 1-acetylpiperidin-4-yl, 1-methylsulfonylpiperidin-4-yl,

4-fluorobenzyl, a phenyl, a difluorocyclohexyl, an ethylcyclohexyl and a phenoxymethyl.

6. The compound according to claim 4 , a pharmaceutically acceptable salt, enantiomer, diastereoisomer, racemate or mixture thereof, wherein R 6 is selected from a group consisting of H, a methyl and an ethyl.

7. The compound according to claim 4 , a pharmaceutically acceptable salt, enantiomer, diastereoisomer, racemate or mixture thereof, wherein R 7 is selected from a group consisting of H, C(═O)R 8 and SO 2 R 8 .

8. The compound according to claim 4 , a pharmaceutically acceptable salt, enantiomer, diastereoisomer, racemate or mixture thereof, wherein said substituent on each of R 8 and R 9 is selected from a group consisting of halogen, a hydroxy, a methoxy, an ethoxy, a methyl, an ethyl, a trifluoromethyl, a trifluoromethoxy, a cyano, a nitro, an amino and a carboxyl.

9. The compound according to claim 7 , a pharmaceutically acceptable salt, enantiomer, diastereoisomer, racemate or mixture thereof, wherein each of R 3 , R 4 and R 5 is independently selected from a group consisting of H, a methyl, an ethyl, an n-propyl, an isopropyl, an n-butyl, a sec-butyl, a tertiary butyl, a cyclopropyl, a cyclobutyl, a cyclopentyl and a cyclohexyl.

10. The compound according to claim 9 , a pharmaceutically acceptable salt, enantiomer, diastereoisomer, racemate or mixture thereof, wherein each of R 3 , R 4 and R 5 is independently selected from a group consisting of H, a methyl, an ethyl, an n-propyl, an isopropyl, an n-butyl, a sec-butyl, a tertiary butyl and a cyclopropyl.

11. The compound according to claim 4 , a pharmaceutically acceptable salt, enantiomer, diastereoisomer, racemate or mixture thereof, wherein each of R 8 and R 9 is independently selected from a group consisting of H, a C1-C4 straight or branched alkyl, a C1-C4 straight or branched haloalkyl, a C3-C7 cycloalkyl, a benzyl and a phenyl.

12. The compound according to claim 11 , a pharmaceutically acceptable salt, enantiomer, diastereoisomer, racemate or mixture thereof, wherein each of R 8 and R 9 is independently selected from a group consisting of a methyl, an ethyl, an n-propyl, a cyclopropyl, an isopropyl, an n-butyl, a sec-butyl and a tert-butyl.

13. The compound according to claim 1 , a pharmaceutically acceptable salt, enantiomer, diastereoisotner, racemate or mixture thereof, wherein, the compound of formula (I) is selected from the following compounds:

14. The compound according to claim 1 , a pharmaceutically acceptable salt, enantiomer, diastereoisotner, racemate or mixture thereof, wherein, the compound of formula I is selected from the following compounds:

wherein, the definitions of R 1 , R 2 , R 3 , R 4 , R 5 , R 6 and W are described as those in claim 1 .

15. The compound according to claim 3 , a pharmaceutically acceptable salt, enantiomer, diastereoisomer, racemate or mixture thereof, wherein,

in formula (II),

R 1 is selected from the following groups unsubstituted or substituted with 1-3 substituents:

 said substituent is defined as claim 1 ;

each of R 10 and R 11 is independently selected from a group consisting of H, a C1-C4 straight or branched alkyl and —C(═O)R 13 ;

R 12 is selected from a group consisting of a C1-C4 straight or branched alkyl, a C1-C4 straight or branched alkoxy, a hydroxy, an amino (NH 2 ) and a C1-C4 straight or branched alkylamino;

R 13 is selected from a group consisting of H and a C1-C4 straight or branched alkyl;

R 2 is selected from the following groups unsubstituted or substituted with 1-3 substituents: a phenyl, a C1-C4 straight or branched alkyl, a C3-C7 cycloalkyl, a tetrahydropyran-4-yl, 1-methylpiperidin-4-yl, 1-acetylpiperidin-4-yl, 1-methylsulfonylpiperidin-4-yl,

 wherein said substituent is selected from a group consisting of a halogen, a hydroxy, a C1-C4 straight or branched alkyl, a C1-C4 straight or branched haloalkyl, a C1-C4 straight or branched alkoxy, a C1-C4 straight or branched alkylcarbonyl, a C1-C4 straight or branched haloalkoxy, a C1-C4 straight or branched alkylsulfonyl, a C1-C4 straight or branched alkylsulfonylcarbamoyl, a tetrazolyl, an amino, a phenyl, a halophenyl, a phenoxy and a halophenoxy;

each of R 3 , R 4 and R 5 is independently selected from a group consisting of H and a C1-C4 straight or branched alkyl;

in formula (III),

R 1 is selected from the following groups unsubstituted or substituted with 1-3 substituents:

 said substituent is defined as claim 1 ;

each of R 10 and R 11 is independently selected from a group consisting of H, a C1-C4 straight or branched alkyl and —C(═O)R 13 ;

R 12 is selected from a group consisting of a C1-C4 straight or branched alkyl, a C1-C4 straight or branched alkoxy, a hydroxy, an amino (NH 2 ) and a C1-C4 straight or branched alkylamino;

R 13 is selected from a group consisting of H and a C1-C4 straight or branched alkyl;

R 2 is selected from the following groups unsubstituted or substituted with 1-3 substituents: a C1-C4 straight or branched alkyl, a C3-C7 cycloalkyl, a tetrahydropyran-4-yl, 1-methylpiperidin-4-yl, 1-acetylpiperidin-4-yl, 1-methylsulfonylpiperidin-4-yl,

 wherein said substituent is selected from a halogen, a hydroxy, a C1-C4 straight or branched alkyl, a C1-C4 straight or branched haloalkyl, a C1-C4 straight or branched alkoxy, a C1-C4 straight or branched alkylcarbonyl, a C1-C4 straight or branched haloalkoxy, a C1-C4 straight or branched alkylsulfonyl, a C1-C4 straight or branched alkylsulfonylcarbamoyl, a tetrazolyl, a cyano and an amino;

each of R 3 and R 4 is independently selected from a group consisting of H and a C1-C4 straight or branched alkyl;

R 5 and R 6 can bind together with

to form

R 7 is selected from a group consisting of H, C(═O)R 8 , C(═O)OR 8 , C(═O)NR 8 R 9 and SO 2 R 8 ;

each of R 8 and R 9 is independently selected from a group consisting of H and the following groups unsubstituted or substituted with 1-3 substituents: a C1-C4 straight or branched alkyl, a C1-C4 straight or branched haloalkyl, a C3-C7 cycloalkyl and a benzyl, wherein, said substituent is selected from a group consisting of a halogen, a hydroxy, a C1-C4 straight or branched alkoxy, a C1-C4 straight or branched alkyl, a C1-C4 straight or branched haloalkyl, a C1-C4 straight or branched haloalkoxy and an amino.

16. The compound according to claim 4 , a pharmaceutically acceptable salt, enantiomer, diastereoisomer, racemate or mixture thereof, wherein,

in formula (II),

said substituent on R 1 is selected from a group consisting of a halogen, a C1-C2 alkyl, a C1-C2 haloalkyl, a C1-C2 alkylcarbonyloxy, a C1-C2 alkoxy, a C1-C2 haloalkoxy, NR 10 , —C(═O)R 12 , a cyano, a nitro and a hydroxyl, or two adjacent R 1 substituents with the atoms to which each is attached are combined to form a fused 5-7 membered carbocycle, a 5-7 membered heteroaryl ring or a 5-7 membered heterocycle.

17. The compound according to claim 16 , a pharmaceutically acceptable salt, enantiomer, diastereoisomer, racemate or mixture thereof, wherein said substituent on R 1 is selected from a group consisting of a halogen, a methyl, a trifluoromethyl, a trilluoromethoxy, a methoxy, an ethyl, an amino, a cyano, a nitro, an acetyl, a formamido, an acetamido, a carbamoyl, N-methylcarbamoyl, N,N-dimethylcarbamoyl, an acetoxy, a formyloxy and a methoxycarbonyl, or two adjacent R 1 substituents together with the atoms to which each is attached form a benzene ring, a cyclopentane ring or dioxole ring.

18. The compound according to claim 4 , a pharmaceutically acceptable salt, enantiomer, diastereoisomer, racemate or mixture thereof, wherein,

in formula (II),

each of R 10 and R 11 is independently selected from a group consisting of a C1-C2 alkyl and —C(═O)R 13 .

19. The compound according to claim 4 , a pharmaceutically acceptable salt, enantiomer, diastereoisomer, racemate or mixture thereof, wherein,

in formula (II),

R 12 is selected from a group consisting of a C1-C2 alkyl, a C1-C2 alkoxy, a hydroxy, an amino (NH 2 ) and a C1-C2 alkylamino.

20. The compound according to claim 4 , a pharmaceutically acceptable salt, enantiomer, diastereoisomer, racemate or mixture thereof, wherein,

in formula (II),

R 13 is selected from a group consisting of H and a C1-C2 straight or branched alkyl.

21. The compound according to claim 4 , a pharmaceutically acceptable salt, enantiomer, diastereoisomer, racemate or mixture thereof, wherein,

in formula (II),

R 2 is selected from a group consisting of a methyl, an ethyl, a cyclopropyl, a cyclobutyl, a cyclopentyl, a cyclohexyl, a tetrahydropyran-4-yl, 1-methylpiperidin-4-yl, 1-acetylpiperidin-4-yl, 1-methylsulfonylpiperidin-4-yl,

 a phenyl, 4-fluorobenzyl, an ethylcyclohexyl and a difluorocyclohexyl.

22. The compound according to claim 15 , a pharmaceutically acceptable salt, enantiomer, diastereoisomer, racemate or mixture thereof, wherein,

in formula (11),

each of R 3 , R 4 and R 5 is independently selected from a group consisting of H and a methyl, an ethyl, an n-propyl, an isopropyl, an n-butyl, a sec-butyl and a tert-butyl.

23. The compound according to claim 22 , a pharmaceutically acceptable salt, enantiomer, diastereoisomer, racemate or mixture thereof, wherein each of R 3 , R 4 and R 5 is independently selected from a group consisting of H, a methyl, an ethyl, an n-propyl and an isopropyl.

24. The compound according to claim 4 , a pharmaceutically acceptable salt, enantiomer, diastereoisotner, racemate or mixture thereof; wherein,

in formula (III),

said substituent on R 1 is selected from a group consisting of a halogen, a C1-C2 alkyl, a C1-C2 haloalkyl, a C1-C2 alkoxy, a C1-C2 alkylcarbonyloxy, a C1-C2 haloalkoxy, NR 10 R 11 , —C(═O)R 12 , a cyano, a nitro and a hydroxyl, or two adjacent R 1 substituents with the atoms to which each is attached are combined to form a fused 5-7 membered carbocycle, 5-7 membered heteroaryl ring or 5-7 membered heterocycle.

25. The compound according to claim 24 , a pharmaceutically acceptable salt, enantiomer, diastereoisomer, racemate or mixture thereof, wherein said substituent on R 1 is selected from a group consisting of a halogen, a methyl, a trifluoromethyl, a trifluoromethoxy, a methoxy, an ethyl, an amino, a cyano, a nitro, an acetyl, a forrnamido, an acetamido, a carbamoyl, N-methylcarbamoyl, N,N-dimethylcarbamoyl, a formyloxy, an acetoxy and a methoxycarbonyl, or two adjacent R 1 substituents together with the atoms to which each is attached form a benzene ring, a cyclopentene ring or dioxole ring.

26. The compound according to claim 15 , a pharmaceutically acceptable salt, enantiomer, diastereoisomer, racemate or mixture thereof, wherein,

in formula (III),

each of R 10 and R 11 is independently selected from a group consisting of H, a C1-C2 alkyl and —C(═O)R 13 .

27. The compound according to claim 15 , a pharmaceutically acceptable salt, enantiomer, diastereoisomer, racemate or mixture thereof, wherein,

in formula (III),

R 12 is selected from a group consisting of a C1-C2 alkyl, a C1-C2 alkoxy, a hydroxy, an amino (NH 2 ) and a C1-C2 alkylamino.

28. The compound according to claim 15 , a pharmaceutically acceptable salt, enantiomer, diastereoisomer, racemate or mixture thereof, wherein,

in formula (III),

R 13 is selected from a group consisting of H and a C1-C2 straight or branched alkyl.

29. The compound according to claim 15 , a pharmaceutically acceptable salt, enantiomer, diastereoisomer, racemate or mixture thereof, wherein,

in formula (III),

R 2 is selected from a group consisting of a methyl, an ethyl, a cyclopropyl, a cyclobutyl, a cyclopentyl, a cyclohexyl, a tetrahydropyran-4-yl, 1-methylpiperidin-4-yl, 1-acetylpiperidin-4-yl, 1-methylsulfonylpiperidin-4-yl,

 and a difluorocyclohexyl.

30. The compound according to claim 15 , a pharmaceutically acceptable salt, enantiomer, diastereoisomer, racemate or mixture thereof, wherein,

in formula (III),

each of R 3 and R 4 is independently selected from a group consisting of H and a methyl, an ethyl, an n-propyl, an isopropyl, an n-butyl, a sec-butyl and a tert-butyl.

31. The compound according to claim 30 , a pharmaceutically acceptable salt, enantiomer, diastereoisomer, racemate or mixture thereof, wherein each of R 3 and R 4 is independently selected from a group consisting of H, a methyl and an ethyl.

32. The compound according to claim 15 , a pharmaceutically acceptable salt, enantiomer, diastereoisomer, racemate or mixture thereof, wherein,

in formula (III),

R 7 is selected from a group consisting of H, C(═O)R 8 and SO 2 R 8 .

33. The compound according to claim 15 , a pharmaceutically acceptable salt, enantiomer, diastereoisomer, racemate or mixture thereof, wherein,

in formula (III),

said substituent on each of Rs and Ry is selected from a group consisting of a halogen, a hydroxy, a methoxy, an ethoxy, a methyl, an ethyl, a trilluoromethyl, a trifluoromethoxy and an amino.

34. The compound according to claim 15 , a pharmaceutically acceptable salt, enantiomer, diastereoisomer, racemate or mixture thereof, wherein,

in formula

each of R 8 and R 9 is independently selected from a group consisting of H, a C1-C4 straight or branched alkyl, a C1-C4 straight or branched haloalkyl and a C3-C7 cycloalkyl.

35. The compound according to claim 33 , a pharmaceutically acceptable salt, enantiomer, diastereoisomer, racemate or mixture thereof, wherein each of R 8 and R 9 is independently selected from a group consisting of a methyl, an ethyl, an n-propyl, a cyclopropyl, an isopropyl, an n-butyl, a sec-butyl and a tert-butyl.

36. The compound according to claim 15 , a pharmaceutically acceptable salt, enantiomer, diastereoisomer, racemate or mixture thereof, wherein each of R 3 , R 4 and R 5 is independently selected from a group consisting of H and a methyl, an ethyl, an n-propyl, an isopropyl, an n-butyl, a sec-butyl and a tert-butyl.

37. The compound according to claim 15 , a pharmaceutically acceptable salt, enantiomer, diastereoisomer, racemate or mixture thereof, wherein each of R 8 and R 9 is independently selected from a group consisting of a halogen, a hydroxy, a methoxy, an ethoxy, a methyl, an ethyl, a trifluoromethyl, a trifluoromethoxy and an amino.

38. A pharmaceutical composition comprising one of the compounds according to claim 1 , a pharmaceutically acceptable salt, enantiomer, diastereoisomer, racemate or mixture thereof; and optionally a pharmaceutically acceptable carrier.

39. A method for treating HIV infection comprising administering to a subject in need thereof, a compound according to claim 1 , a pharmaceutically acceptable salt, enantiomer, diastereoisomer, racemate or mixture thereof.

40. A method for preparing a medicament for treating a CCR5-mediated disease comprising combining a compound according to claim 1 , a pharmaceutically acceptable salt, enantiomer, diastereoisomer, racemate or mixture thereof with a pharmaceutically acceptable carrier.

41. A method for preparing a compound of formula I, wherein, the method includes the following steps:

1) Sulfinylimine Compound B is obtained from Compound A through imidization;

2) Compound C is Obtained from Sulfinylimine compound B through Mannich reaction;

3) Compound D is obtained from Compound C through removal of sulfinyl and t-butyloxycarbonyl (BOC) protection;

4) Compound E is obtained from Compound D through ester reduction and oxidation;

5) Compound F is obtained from Compound E and

 through reductive amination reaction;

6) Compound F is subjected to deprotection and condensation reaction with

 to give compound I,

in each formula, R 1 , R 2 , R 4 , R 5 , R 6 , X and W are defined as those in claim 1 .